HYDROFLUMETHIAZIDE AND RESERPINE
Clinical safety rating: safe
MAOIs can cause excitability and hypertension Can cause depression and suicidal ideation.
Hydroflumethiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, reducing sodium and water reabsorption. Reserpine is an indole alkaloid that depletes catecholamines from central and peripheral nerve endings by binding to and inhibiting the vesicular monoamine transporter (VMAT), leading to reduced sympathetic outflow and vasodilation.
| Metabolism | Hydroflumethiazide: minimally metabolized, primarily excreted unchanged in urine. Reserpine: extensively metabolized in the liver via hydrolysis and conjugation, with some deacetylation; active metabolites are formed. |
| Excretion | Hydroflumethiazide: Primarily renal excretion (60-80% as unchanged drug), with minor biliary/fecal elimination (10-20%). Reserpine: Extensive hepatic metabolism; metabolites excreted renally and fecally. Less than 1% of reserpine is excreted unchanged in urine. |
| Half-life | Hydroflumethiazide: Terminal half-life 12-15 hours, supporting once- or twice-daily dosing. Reserpine: Terminal half-life 50-100 hours (average 70 hours), requiring days to weeks for full washout; clinical effects persist beyond drug presence due to irreversible binding to vesicular monoamine transporters. |
| Protein binding | Hydroflumethiazide: ~50-70% bound to plasma proteins (primarily albumin). Reserpine: >95% bound to plasma proteins (albumin and alpha-1-acid glycoprotein). |
| Volume of Distribution | Hydroflumethiazide: Vd 0.4-0.6 L/kg, indicating distribution primarily in extracellular fluid. Reserpine: Vd 1-2 L/kg, reflecting extensive tissue binding (adipose, brain, adrenergic neurons). |
| Bioavailability | Hydroflumethiazide: Oral bioavailability ~70% (first-pass metabolism <30%). Reserpine: Oral bioavailability ~50% due to extensive hepatic first-pass metabolism. |
| Onset of Action | Hydroflumethiazide: Diuretic effect begins within 2 hours (oral), peak at 4-6 hours. Reserpine: Hypotensive effect onset delayed (3-7 days oral) due to gradual depletion of catecholamines; full effect may require 2-3 weeks. |
| Duration of Action | Hydroflumethiazide: Duration 12-24 hours (oral). Reserpine: Hypotensive effect lasts 1-2 weeks after drug discontinuation due to irreversible monoamine depletion; recovery of normal catecholamine levels may take weeks. |
| Molecular Weight | Hydroflumethiazide: 331.31 Da; Reserpine: 608.68 Da |
One tablet (hydroflumethiazide 50 mg / reserpine 0.125 mg) orally once daily.
| Dosage form | TABLET |
| Renal impairment | Contraindicated if GFR <30 mL/min. For GFR 30-50 mL/min, use with caution and monitor electrolytes; no standard dose reduction specified. |
| Liver impairment | Contraindicated in severe hepatic impairment (Child-Pugh class C). Use with caution in moderate impairment (Child-Pugh class B); no specific dose adjustment provided. |
| Pediatric use | Not recommended due to lack of safety and efficacy data in pediatric patients. |
| Geriatric use | Initiate at lowest possible dose (e.g., half tablet daily) to minimize orthostatic hypotension and electrolyte disturbances; monitor renal function and electrolytes closely. |
| 1st trimester | Hydroflumethiazide: Use only if potential benefit justifies risk. Thiazides cross placenta and may cause fetal/neonatal jaundice, thrombocytopenia, and electrolyte disturbances. Reserpine: Contraindicated; crosses placenta and associated with increased risk of respiratory depression, nasal congestion, and hypothermia in neonates. |
| 2nd trimester | Hydroflumethiazide: Use only if clearly needed; may decrease placental perfusion. Reserpine: Contraindicated due to neonatal adverse effects. |
| 3rd trimester | Hydroflumethiazide: Use only if clearly needed; may cause neonatal electrolyte imbalance, jaundice, or thrombocytopenia. Reserpine: Contraindicated due to risk of neonatal respiratory depression and nasal congestion. |
Clinical note
MAOIs can cause excitability and hypertension Can cause depression and suicidal ideation.
| FDA category | Animal |
| Placental transfer | Both components cross the placenta. Hydroflumethiazide: Demonstrated placental transfer. Reserpine: Readily crosses placenta and can cause neonatal effects. |
■ FDA Black Box Warning
None.
| Common Effects | Depression |
| Serious Effects |
Hypersensitivity to hydroflumethiazide, reserpine, or sulfonamide-derived drugsAnuriaPregnancy (reserpine component)Concurrent use with MAOIs (reserpine component)Active peptic ulcer disease (reserpine)Ulcerative colitis (reserpine)Severe renal impairment (CrCl <30 mL/min)Electrolyte abnormalities (e.g., hypercalcemia, hypokalemia, hyponatremia) uncorrected before therapy
| Precautions | Electrolyte imbalances (hypokalemia, hyponatremia, hypomagnesemia), hyperuricemia, hyperglycemia, hypotension, mental depression, peptic ulcer disease, and pancreatitis. |
| Food/Dietary | Avoid excessive intake of potassium-rich foods (e.g., bananas, citrus, spinach) if not instructed; but typically not a concern with thiazides unless hypokalemia develops. Avoid high-sodium foods as they counteract antihypertensive effect. Grapefruit juice may increase reserpine levels; avoid large amounts. Limit alcohol as it may enhance hypotensive effects. |
Loading safety data…
| Breastfeeding | Hydroflumethiazide is excreted in breast milk in low amounts, generally considered compatible with breastfeeding but may suppress lactation and cause electrolyte disturbances in infant. Reserpine is excreted in breast milk and may cause adverse effects such as nasal congestion, drowsiness, and diarrhea in the nursing infant. Due to reserpine's risks, avoid breastfeeding during therapy. |
| Lactation Rating | L4 - Possibly Hazardous |
| Teratogenic Risk | Pregnancy Category C. First trimester: thiazides cross placenta, possible placental insufficiency. Second/third trimester: risk of fetal/neonatal jaundice, thrombocytopenia, electrolyte disturbances. Reserpine increases risk of neonatal respiratory depression, bradycardia, hypotonia, hypothermia, and poor feeding. |
| Fetal Monitoring | Maternal: blood pressure, serum electrolytes, renal function, CBC. Fetal/neonatal: growth ultrasound, fetal heart rate monitoring, neonatal bilirubin and platelet counts, signs of respiratory depression and electrolyte imbalance. |
| Fertility Effects | Hydroflumethiazide: no known direct effects on fertility. Reserpine: may cause hyperprolactinemia leading to menstrual irregularities, anovulation, and galactorrhea; can impair fertility. Both agents may reduce libido. |
| Clinical Pearls | Combination thiazide (hydroflumethiazide) and rauwolfia alkaloid (reserpine) for hypertension. Reserpine depletes catecholamines; risk of depression, nasal congestion, bradycardia. Hydroflumethiazide causes hypokalemia, hyperglycemia, hyperuricemia. Avoid in patients with history of depression, peptic ulcer, or severe renal impairment. Monitor electrolytes, uric acid, and mood changes. Onset of reserpine effect is slow (weeks); do not use for hypertensive emergencies. |
| Patient Advice | Take exactly as prescribed; do not double doses. · If you experience mood changes, depression, or insomnia, contact your doctor immediately. · Avoid sudden discontinuation; follow doctor's instructions for tapering. · May cause dizziness, drowsiness, or lightheadedness; avoid driving if affected. · Report unusual bleeding, bruising, or signs of infection. · Do not take over-the-counter cough, cold, or allergy medications without consulting pharmacist. · Be sure to drink enough water, but not to overhydrate; discuss fluid intake with your doctor. · May increase blood sugar; monitor if diabetic. · Avoid prolonged sun exposure; use sunscreen and protective clothing. · If you miss a dose, take it as soon as remembered unless close to next dose; skip missed dose if near next dose. |